A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves safe and effective.
Patients with moderate to severe Crohn's disease considering trial participation, clinicians who refer to trials, and researchers tracking investigational biologics (anti-TL1A).
What To Know
This is a Phase 3 clinical trial record testing tulisokibart (MK-7240), an investigational anti-TL1A antibody, for moderate to severe Crohn's disease. People with Crohn's disease may be interested because the study is evaluating whether at least one dose is superior to placebo for achieving clinical remission.
This ClinicalTrials.gov record describes a randomized, interventional Phase 3 study currently recruiting participants with moderately to severely active Crohn's disease. The trial will compare one or more doses of tulisokibart to placebo with clinical remission (by Crohn's Disease Activity Index) as a primary efficacy endpoint.
Standard eligibility exclusions are listed, including recent bowel surgery, certain infections (active TB, HBV/HCV/HIV), recent cancer, prior exposure to this drug or other anti-TL1A antibodies, and other conditions. The record lists multiple U.S. study sites and notes the sponsor as Merck Sharp & Dohme LLC.
It is a trial record (not results), so no findings or safety conclusions are reported here. Patients with moderate to severe Crohn's disease interested in clinical trials, clinicians who refer patients to trials, and researchers following investigational anti-TL1A therapies.
This is a trial registration (Phase 3) describing planned study design and eligibility; it does not report outcomes or confirmed safety/effectiveness. Prior exposure to tulisokibart or other anti-TL1A antibodies is exclusionary, and many common infections and recent cancer are excluded.
This is a Phase 3 study registration without posted results. The record lists eligibility criteria and exclusion conditions; it does not provide efficacy or safety outcomes. Treat this as a trial opportunity/record, not evidence of benefit.
